European studies revealed an ORR of 45% and a median PFS of 19 months for pemetrexed-based chemotherapy, highlighting its enduring efficacy, similar to that observed in ALK and ROS1 fusion-positive NSCLC (18). The gene discussed is ALK; the disease is non-small cell lung carcinoma.